The operating loss amounted to 132.2 million euros in the first six months, as the company announced on Thursday in Tübingen. In the same period last year, it was still 75.6 million euros. The reason given by CureVac included additional costs in connection with the termination of production services for the first-generation Covid 19 vaccine.
In the first half of the year, CureVac recorded a loss before taxes of a good 125 million euros (2022: around 73 million euros). Meanwhile, sales collapsed: CureVac reported 14.7 million euros for the first half of the year after 44.5 million euros a year earlier.
PayPal – stock in the sell-off
All chart analysis can be found on our YouTube channel. Inform now!
The company had withdrawn its first vaccine candidate against Corona from the approval process due to its comparatively low effectiveness. CureVac is working with its British partner GlaxoSmithKline to develop a new second-generation corona vaccine. The start of a phase 2 study for the vaccine was only recently announced. First data are expected in early 2024.
Regarding the patent dispute with BioNTech for a share of the revenue BioNTech generates from vaccine production, CureVac said in the release: “For the past 23 years, CureVac has patented underlying technology related to mRNA design and delivery and the production of the mRNA that has been instrumental in the development of safe and effective Covid-19 vaccines.” BioNTech made billions in sales with its Covid 19 vaccine in the Corona years.
In NASDAQ trading, CureVac shares ultimately lost 8.08 percent to $8.65.
/tat/DP/jha
TÜBINGEN (dpa-AFX)
Image source: Matthias Hangst/Getty Images